# A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)

Study · id `cardio:ct-nct06024746` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06024746](<https://clinicaltrials.gov/study/NCT06024746>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06024746

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1500 participants.

## Technical summary

Registry record NCT06024746. Randomized; no masking; primary purpose treatment. Start 2024-07-09 (actual); primary completion 2027-11 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1500 participants (planned count; ClinicalTrials.gov record NCT06024746, source copy `cardio:ctgov-nct06024746-2026-09-10`, retrieved 2026-10-26)
- Started: 2024-07-09 (actual) (ClinicalTrials.gov record NCT06024746, source copy `cardio:ctgov-nct06024746-2026-09-10`, retrieved 2026-10-26)
- Primary completion: 2027-11 (anticipated) (ClinicalTrials.gov record NCT06024746, source copy `cardio:ctgov-nct06024746-2026-09-10`, retrieved 2026-10-26)
- Completion: 2027-11 (anticipated) (ClinicalTrials.gov record NCT06024746, source copy `cardio:ctgov-nct06024746-2026-09-10`, retrieved 2026-10-26)
- Countries: United States; Brazil; Canada; China; India; Spain; Sri Lanka; United Kingdom (ClinicalTrials.gov record NCT06024746, source copy `cardio:ctgov-nct06024746-2026-09-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06024746-2026-09-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)
- Acronym: CONFIRMATION
- Condition: Heart Failure
- Intervention (Drug): Finerenone
- Intervention (Drug): Empagliflozin
- Lead sponsor: Colorado Prevention Center
- Lead sponsor class: OTHER
- Collaborator: Saint Luke's Mid America Heart Institute
- Collaborator class: UNKNOWN
- Collaborator: Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry intervention name matches this record: Finerenone (`cardio:finerenone`)
- Registry intervention name matches this record: Empagliflozin (`cardio:empagliflozin`)
- Registry lists this organization as the lead sponsor: Colorado Prevention Center (`cardio:org-colorado-prevention-center`)
- Registry lists this organization as a collaborator: Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma (`cardio:org-bayer-healthcare-pharmaceuticals-inc-bayer-schering-pharma`)

## Provenance

Content hash: 0c85a31c09b62f3dd471cd8b6c7dd3ad8182bc0aa7909d1e9ed8ca13934ba3dd
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
